INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 32 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $1,858,500,000 | – | 14,000,000 | – | 3.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PenderFund Capital Management Ltd. | 11,795,000 | $10,081,000 | 2.79% |
| Context Capital Management, LLC | 9,795 | $6,281,000 | 0.45% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 225,000 | $144,000 | 0.02% |
| Calamos Advisors LLC | 5,000,000 | $3,209,000 | 0.01% |
| FRANKLIN RESOURCES INC | 21,000,000 | $13,885,000 | 0.01% |
| FMR LLC | 17,435,000 | $11,397,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| MORGAN STANLEY | 1,601,000 | $1,036,000 | 0.00% |